News
Johnson & Johnson has moved a step closer to filing a potential first-in-class therapy for psoriasis after the drug hit the mark in a phase 3 trial. Once-daily oral IL-23 inhibitor icotrokinra ...
School of Electronics, Electrical Engineering and Computer Science, Queen’s University Belfast, Belfast BT7 1NN, U.K.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback